EyePoint Pharmaceuticals

Investor FAQs

Watertown, Massachusetts

Delaware

Founded in Australia, pSivida was incorporated in the U.S. in June 2008

June 30th

EyePoint Pharmaceuticals stock is traded on the NASDAQ (PSDV), Australian (PVA), and Frankfurt (PV3) exchanges

We have license agreements with Bausch and Lomb for both the Vitrasert product and the Retisert product. We also have a license agreement with Alimera for ocular applications of the ILUVIEN device. We have a collaboration agreement with Pfizer for the Durasert device delivering latanoprost.

We have 2 FDA approved products, Vitrasert and Retisert. Both are being sold by Bausch and Lomb. ILUVIEN received a positive outcome from the EU Decentralized Procedure and has subsequently received formal marketing authorization in the U.K., Austria, France, Germany, Portugal, Spain,Italy, Norway and Denmark.

Computershare Investor Services

In the United States contact:


Argot Partners
Kimberly Minarovich
(646) 368-8014
kimberly@argotpartners.com

Joseph Rayne
(617) 340-6075
joseph@argotpartners.com
 

Contact:

Computershare Investor Services
P.O. Box 43078
Providence, RI 02940
United States of America
Phone: 781-575-2879
Fax: 781-575-3605

No

Deloitte & Touche, LLP

Ropes & Gray, LLP

Please submit your question using the form below. * Required fields

 
 
 
 
 
 
This helps EyePoint Pharmaceuticals prevent automated submissions.
 

Search Investor Relations

EyePoint Pharmaceuticals